Wire · opportunities
Ichnos Glenmark Files IND for ISB 2301 Cancer Drug
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 November 2026 · Fusion42 review
Ichnos Glenmark Innovation has filed an Investigational New Drug application with the FDA for ISB 2301, a pentaspecific immune cell activator targeting solid tumours, with Phase 1 trials planned for 2027.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You should update your drug pipeline plans now that multi-target immune therapies are moving into solid tumour trials backed by regulatory progress. The outcome of the upcoming Phase 1 trial will define whether you can enter this competitive approach against immune-resistant cancers.
◆ Coverage
1 source · 22 Nov 2026
◆ Related on Wire
◆ Topics